Study finds no elevated risk of thyroid cancer among GLP1-RA users
A study has found no evidence that glucagon-like peptide 1 receptor agonist (GLP1-RA) use is associated with an increased risk of thyroid cancer.
Read More
Survey shows previous experience affects family planning decisions of people with hereditary dementia
Living in a family where there is genetic risk for dementia significantly affects choices about having children and how to parent, finds a study led by UCL researchers.
Doctors, nurses press ahead as wildfires strain Los Angeles’ health care
The rapidly spreading wildfires that have transformed much of Los Angeles County into a raging hellscape are not only upending the lives of tens of thousands of residents and business owners, but also stressing the region’s hospitals, health clinics, first responders, and nursing homes.
Wildfire smoke from the LA fires: A hidden health cost
Los Angeles has experienced some of the world’s worst air quality this week as smoke from massive wildfires blankets the region and threatens the health of far more people than the fires themselves. And that will end up adding to the economic toll.
Indiana state senator moves to scrap hospital monopoly law he helped create
On the heels of a scuttled hospital merger between rivals in Terre Haute, Indiana, a state senator introduced a bill that would forbid similar mergers in the future.
Software tool provides a new view inside complex 3D biomedical images
Researchers have developed a new software tool that provides unprecedented capabilities to see inside 3D images. Its interactive, dynamic cutaway views allowed them to analyze never-before-seen dynamics of embryonic mouse heart development using optical coherence tomography (OCT) images.
IMVARIA Receives 510(k) Clearance for ScreenDx, a First-of-its-Kind Screening Algorithm to Assess for Interstitial Lung Disease
BERKELEY, Calif.–(BUSINESS WIRE)– #510k–IMVARIA Inc., a health tech company pioneering AI-driven digital biomarker solutions, today announced its second FDA authorization, securing 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its ScreenDx solution, an AI-powered healthcare tool to assist clinicians in assessing for interstitial lung disease (ILD). “ScreenDx is a software‐only device leveraging artificial intelligence to analyze CT imaging data for findings suggestive of inte
Datopotamab deruxtecan granted Priority Review in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer
WILMINGTON, Del.–(BUSINESS WIRE)–AstraZeneca and Daiichi Sankyo’s Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted and granted Priority Review in the US for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) who have received prior systemic therapies, including an EGFR-directed therapy. The Food and Drug Administration (FDA) grants Priority Review to
Advanced Infusion Care (AIC) now offers GC Biopharma’s ALYGLO™ [Immune Globulin Intravenous (Human-stwk) 10% liquid]
DALLAS–(BUSINESS WIRE)–AIC, a division of AIS Healthcare, now offers ALYGLO™, manufactured by GC Biopharma, for the treatment of patients with primary humoral immunodeficiency (PI) in adults. This includes, but is not limited to, the humoral immune defect in congenital agammaglobulinemia, common variable immunodeficiency (CVID), X-linked agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiency (SCID). The nationally accredited home infusion teams at AIC collaborate c
CareDx Announces Preliminary Fourth Quarter and Full Year 2024 Results
BRISBANE, Calif.–(BUSINESS WIRE)–CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – today reported preliminary, unaudited financial results for the fourth quarter and full year ended December 31, 2024. Preliminary Fourth Quarter 2024 Financial Results Revenue is expected to be between $85 million and $86 million, an increase of approximately 30% year-over-year. Testing services revenue is expected to be between $62.5 million and $63.5 million, an increase of approximately 35% year-over-y